Patents Assigned to FINA BIOTECH, S.L.
-
Patent number: 9902998Abstract: Non-invasive diagnostic methods for diagnosing bladder cancer are based on determining the expression level of one or more markers. The one of the markers comprises the IGF2 gene in a sample from the subject to be studied. Other suitable markers include MAGEA3, ANXAIO, AHNAK2, CTSE, CRH, KLF9, KRT20, POSTN, PPP1R14D, SLCIA6, TERT, ASAM, MCMIO, EBF1, CFH and MMP12 and possibly FOXM1, KIF20A, MELK, CDK1.Type: GrantFiled: January 31, 2014Date of Patent: February 27, 2018Assignee: FINA BIOTECH, S.L.Inventors: Antonio Alcaraz Asensio, Lourdes Mengual Brichs, Maria Jose Ribal Caparros, Juan José Lozano Salvatella
-
Patent number: 9097715Abstract: A high sensitive and specific non-invasive bladder cancer diagnosis and/or prognosis method based on the detection and quantification of the gene expression of a combination of bladder tumor markers in bladder fluids is provided. A preferred combination of the markers consists of the combination of ANXA10, C14orf78, CTSE, CRH, IGF2, KLF9, KRT20, MAGEA3, POSTN, PPP1R14D, SLC1A6, TERT, ASAM and MCM10 genes.Type: GrantFiled: June 5, 2007Date of Patent: August 4, 2015Assignee: FINA BIOTECH, S.L.U.Inventors: Antonio Alcaraz Asensio, Lourdes Mengual Brichs, Moises Burset Albareda, Maria Jose Ribal Caparros, Elisabet Ars Criach
-
Patent number: 8053189Abstract: The object of the present invention refers to an in vitro method for diagnosing colorectal cancer based on the determination from a biological sample obtained from a subject, of promoter methylation status of at least one of the genes APC, RARB2 and p14 and, optionally, MGMT and p16. Likewise, object of the present invention is a kit for performing the method of the invention.Type: GrantFiled: November 3, 2008Date of Patent: November 8, 2011Assignee: Fina Biotech, S.L.U.Inventors: Gabriel Capella Munar, Daniel Azuara García
-
Patent number: 8008015Abstract: Methods and kits for diagnosing the risk of developing restenosis after revascularization by implantation of stents based on the detection of single-nucleotide polymorphisms (SNPs).Type: GrantFiled: February 24, 2009Date of Patent: August 30, 2011Assignee: Fina Biotech, S.L.U.Inventors: Vicente Andres Garcia, Carlos Silvestre Roig, Patricia Fernandez Ferri, Pedro Luis Sanchez Fernandez, Francisco Fernandez Aviles, Felipe Javier Chaves Martinez
-
Publication number: 20110123497Abstract: The present invention provides a biocompatible, biodegradable graft composition for regeneration of neural tissue, comprising the following components: a) a gel scaffold formed from an isolated platelet containing fluid and an activating agent comprising calcium chloride, with or without thrombin, b) a nerve growth factor selected from BDNF, NGF, retinoic acid and combinations thereof, and c) a culture of at least 50,000 progenitor stem cells; the method of production and the uses thereof.Type: ApplicationFiled: November 20, 2009Publication date: May 26, 2011Applicant: FINA BIOTECH, S.L.U.Inventors: MERCEDES ZURITA CASTILLO, JESUS VAQUERO CRESPO, CONCEPCION AGUAYO FERRER, LAURA OTERO ORTEGA
-
Publication number: 20100216124Abstract: Methods and kits for diagnosing the risk of developing restenosis after revascularization by implantation of stents based on the detection of single-nucleotide polymorphisms (SNPs).Type: ApplicationFiled: February 24, 2009Publication date: August 26, 2010Applicant: FINA BIOTECH, S.L.U.Inventors: Vicente Andres Garcia, Carlos Silvestre Roig, Patricia Fernandez Ferri, Pedro Luis Sanchez Fernandez, Francisco Fernandez Aviles, Felipe Javier Chaves Martinez
-
Publication number: 20100112555Abstract: The object of the present invention refers to an in vitro method for diagnosing colorectal cancer based on the determination from a biological sample obtained from a subject, of promoter methylation status of at least one of the genes APC, RARB2 and p14 and, optionally, MGMT and p16. Likewise, object of the present invention is a kit for performing the method of the invention.Type: ApplicationFiled: November 3, 2008Publication date: May 6, 2010Applicant: FINA BIOTECH, S.L.U.Inventors: Gabriel CAPELLA MUNAR, Daniel AZUARA GARCIA
-
Publication number: 20080318221Abstract: The present invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease by means of determining the DARC gene expression level in a biological sample and comparing said level with a reference value, in which the disturbance of said level is indicative of Alzheimer's disease.Type: ApplicationFiled: June 20, 2007Publication date: December 25, 2008Applicants: FINA BIOTECH, S.L., ORYZON GENOMICS, S.A.Inventors: Elisabet Rosell Vives, Marta Barrachina Castillo, Isidro Ferrer Abizanda, Tamara Maes
-
Publication number: 20080318220Abstract: The present invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease by means of determining the ZMIZ1 gene expression level in a biological sample and comparing said level with a reference value, in which the alteration of said level is indicative of Alzheimer's disease.Type: ApplicationFiled: June 20, 2007Publication date: December 25, 2008Applicants: FINA BIOTECH, S.L., ORYZON GENOMICS, S.A.Inventors: Elisabet Rosell Vives, Marta Barrachina Castillo, Isidro Ferrer Abizanda, Tamara Maes
-
Publication number: 20080206762Abstract: The invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease, consisting in determining the expression level of a gene encoding a lysosomal marker.Type: ApplicationFiled: May 17, 2006Publication date: August 28, 2008Applicant: FINA BIOTECH,S.L.U.Inventors: Isidro Ferrer Abizanda, Marta Barrachina Castillo, Francisco Subirada Sole, Olga Maria Durany Turk, Carlos Manuel Buesa Arjol, Tamara Maes
